Why This Research Matters
Ibogaine has shown remarkable promise in early studies for addressing opioid dependence, traumatic brain injury, and treatment-resistant depression. Yet, the lack of large-scale clinical trials remains the single greatest barrier to FDA approval and widespread medical access.
This initiative aims to change that by funding a rigorous, peer-reviewed study conducted in partnership with leading academic institutions.
What the Trial Will Study
- Opioid Use Disorder — Evaluating ibogaine’s ability to reduce withdrawal symptoms and long-term relapse rates
- Traumatic Brain Injury (TBI) — Measuring neuroplasticity improvements in veterans with mild-to-moderate TBI
- Treatment-Resistant Depression — Assessing sustained mood improvements following ibogaine-assisted sessions
How You Can Help
Every dollar contributed goes directly toward participant screening, medical oversight, and data analysis. Our goal is to enroll 200 participants across three study sites by the end of 2026.
Frequently Asked Questions
Is ibogaine legal in the United States? Ibogaine is currently classified as a Schedule I substance at the federal level. However, clinical research exemptions allow approved studies to proceed under strict regulatory oversight.
Who is eligible to participate? Veterans aged 21-65 with a documented history of opioid use disorder or traumatic brain injury may qualify. All participants undergo thorough cardiac and psychological screening.
When will results be available? Preliminary findings are expected in late 2027, with a full publication anticipated in early 2028.